FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance
Go back to FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance| Pfizer Inc. (NYSE: PFE) | Delayed: 25.01 +0.19 (0.77%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $24.82 | 52 Week High | $37.39 | |||
| Open | $24.89 | 52 Week Low | $28.25 | |||
| Day High | $25.10 | P/E | 15.16 | |||
| Day Low | $24.75 | EPS | $1.65 | |||
| Volume | 30,823,442 | |||||
